ViRexx Files Occlusin'TM' Injection CTA With Health Canada.EDMONTON, Alberta -- ViRexx Medical Corp. (TSX VENTURE:VIR) today announced that it has filed a Clinical Trial Application for its lead product candidate, Occlusin(TM) Injection. The phase I clinical trial Noun 1. phase I clinical trial - a clinical trial on a few persons to determine the safety of a new drug or invasive medical device; for drugs, dosage or toxicity limits should be obtained phase I is scheduled to enrol liver cancer patients at the Toronto General Hospital The Toronto General Hospital (TGH), part of the University Health Network, is a major teaching hospital in downtown Toronto, Canada. It is located in the Discovery District, directly north of the Hospital for Sick Children, across Gerrard Street West, and east of Princess of the University Health Network under the direction of principal investigator Morris Sherman, MB BCh, Ph.D., Associate Professor of Medicine at the University of Toronto Research at the University of Toronto has been responsible for the world's first electronic heart pacemaker, artificial larynx, single-lung transplant, nerve transplant, artificial pancreas, chemical laser, G-suit, the first practical electron microscope, the first cloning of T-cells, . "I am extremely pleased that ViRexx has reached this milestone in its clinical program. Occlusin(TM) Injection is the first generation of a series of drugs based on the T-ACT(R) platform technology for the therapy of benign and malignant tumors," commented Dr. Antoine Noujaim, President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of ViRexx Medical Corp. About the T-ACT(TM) Platform The T-ACT(TM) platform technology harnesses the body's natural ability to form a clot to induce site-specific thrombosis of blood vessels feeding solid tumors. Tumors require a constant supply of oxygen and nutrients in order to survive. Blocking the blood supply to a tumor leads to "tumor starvation". Occlusin(TM) Injection is the lead product arising from the T-ACT(TM) technology platform and has been designed as an embolotherapeutic agent to treat solid tumors. Embolotherapy involves the delivery of agents directly to the blood vessels feeding a tumor with the intent of forming a site-specific clot. Occlusin(TM) Injection consists of particles made of human albumin and a key protein found circulating in the blood stream, von Willebrand factor von Willebrand factor (vWF) A protein found in the blood that is involved in the process of blood clotting. Mentioned in: Von Willebrand Disease von Willebrand factor (VWF vWF von Willebrand's factor. von Willebrand factor (vWF) A protein found in the blood that is involved in the process of blood clotting. Mentioned in: Von Willebrand Disease ). VWF normally travels in the blood stream with no effect on blood clotting. However, once immobilized through binding to damaged blood vessels, it initiates a cascade of events that leads to platelet binding, activation and the formation of a clot. Occlusin(TM) Injection is scheduled to begin a Phase I clinical trial in Q3 2004. About ViRexx ViRexx is an Edmonton, Alberta based biotechnology company focused on the development of novel and unique therapeutic products for the treatment of chronic Hepatitis B, Hepatitis C and selected solid tumors. For additional information, please visit www.virexx.com. The TSX Venture Exchange TSX Venture Exchange Originally called the Canadian Venture Exchange (CDNX), this was a result of the merger of the Vancouver and Alberta stock exchanges. The goal of TSX Venture Exchange is to provide venture companies with effective access to capital while protecting investors. does not accept responsibility for the adequacy or accuracy of this release. |
|
Printer friendly
Cite/link
Email
Feedback
Reader Opinion